VBI Vaccines/VBIV

$0.60

-4.84%
-
1D1W1MYTD1YMAX

About VBI Vaccines

VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Ticker

VBIV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jeffrey Baxter

Employees

131

Headquarters

Cambridge, United States

VBI Vaccines Metrics

BasicAdvanced
$17.94M
Market cap
-
P/E ratio
-$9.42
EPS
1.84
Beta
-
Dividend rate
$17.94M
1.8361
$3.47
$0.45
451.52K
0.478
0.366
674.492
-4.28%
-76.71%
-261.8%
-143.53%
2.066
2.014
702.4%
28.43%
101.51%

What the Analysts think about VBI Vaccines

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
733.33% upside
High $5.00
Low $5.00
$0.60
Current price
$5.00
Average price target

VBI Vaccines Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$800K
-87.88%
Net income
$0
-100%
Profit margin
0%
-100%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for VBI Vaccines stock?

VBI Vaccines (VBIV) has a market cap of $17.94M as of April 23, 2024.

What is the P/E ratio for VBI Vaccines stock?

The price to earnings (P/E) ratio for VBI Vaccines (VBIV) stock is 0 as of April 23, 2024.

Does VBI Vaccines stock pay dividends?

No, VBI Vaccines (VBIV) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next VBI Vaccines dividend payment date?

VBI Vaccines (VBIV) stock does not pay dividends to its shareholders.

What is the beta indicator for VBI Vaccines?

VBI Vaccines (VBIV) has a beta rating of 1.84. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the VBI Vaccines stock price target?

The target price for VBI Vaccines (VBIV) stock is $5, which is 733.33% above the current price of $0.6. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell VBI Vaccines stock

Buy or sell VBI Vaccines stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing